Publication:
NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES

Simple item page
dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorElcioglu, Oemer Celal
dc.contributor.authorAkpinar, Timur
dc.contributor.authorCosan, Fulya
dc.contributor.authorUcur, Ali
dc.contributor.authorBayrak, Ayseguel
dc.contributor.authorCefle, Kivanc
dc.contributor.authorOeztuerk, Suekrue
dc.contributor.authorPalanduz, Suekrue
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorAktan, Melih
dc.contributor.authorNalcaci, Meliha
dc.contributor.institutionauthorELÇİOĞLU, ÖMER CELAL
dc.date.accessioned2020-10-29T15:29:17Z
dc.date.available2020-10-29T15:29:17Z
dc.date.issued2010-05-01T00:00:00Z
dc.description.abstractObjective: Clonal cytogenetic aberrations other than Philadelphia chromosome can develop during the course of chronic myeloid leukemia naturally or under the pressure of treatment strategies like interferon, imatinib and dasatinib. Some of them are associated with resistance to treatment and progression to advanced phases of chronic myeloid leukemia. Nilotinib is a second generation thyrosine kinase inhibitor, but its efficacy in chronic myeloid leukemia patients with additional chromosomal changes has not been delineated yet. In this study we evaluated the efficacy of nilotinib in imatinib-resistant or -intolerant t(9;22) positive chronic myeloid leukemia patients with and without additional chromosomal changes
dc.identifier.citationYavuz A. S. , Elcioglu O. C. , Akpinar T., Cosan F., Ucur A., Bayrak A., Cefle K., Oeztuerk S., Palanduz S., Yenerel M. N. , et al., -NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES-, NOBEL MEDICUS, cilt.6, ss.57-62, 2010
dc.identifier.scopus77957317679
dc.identifier.urihttp://hdl.handle.net/20.500.12645/25602
dc.identifier.wosWOS:000281404900011
dc.titleNILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES
dc.typeArticle
dspace.entity.typePublication
local.avesis.id371fab03-737b-483b-89ce-c4c149cd4b85
local.indexed.atWOS
local.indexed.atScopus
local.publication.isinternational1
relation.isAuthorOfPublicationac752d9f-ce71-4152-9eec-135f3d2a7a18
relation.isAuthorOfPublication.latestForDiscoveryac752d9f-ce71-4152-9eec-135f3d2a7a18

Files

Collections

Yayınlar - Eserler